ArticleAnnals of hematology2026
Integrated transcriptome-proteome analysis in patients with myelofibrosis-related anemia.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective. Myelofibrosis (MF) represents a hallmark of the advanced stage of myeloproliferative neoplasms (MPNs), and anemia serves as an independent factor for poor prognosis. Our study aimed to explore the gene and protein profile in patients with MF-related anemia through integrated transcriptome-proteome analysis. Methods. Peripheral blood was collected from 36 MPN patients, including 24 anemic individuals. Isolated mononuclear cells were analyzed for differentially expressed genes (DEGs) via transcriptomic sequencing. Plasma samples was tested for differentially expressed proteins (DEPs) using Olink proteomics technology. Potential diagnostic biomarkers for MF-related anemia were identified though combined Lasso regression, logistic regression analysis, and receiver-operating characteristic curve. Results. Gene set enrichment analysis showed that the JAK-STAT signaling pathway is generally downregulated in anemic patients, and DEGs associated with erythroid differentiation were significantly upregulated in the anemia group. Proteomics analysis indicated that TRAIL and CXCL13 were the most significantly downregulated and upregulated DEPs in anemic patients, respectively. Univariate logistic regression analysis suggested positive correlation between IL-6, IL-10, and PD-L1 with anemia, while only IL-10 remained statistically significant in multivariate analysis. ELISA assay confirmed significantly elevated plasma IL-10 levels in patients with MF-related anemia. Conclusions. DEGs associated with erythroid differentiation are highly expressed in anemic patients, confirming the involvement of ineffective erythropoiesis in the pathogenesis of MF-related anemia. Besides abnormally activated inflammatory cytokines, the anti-inflammatory factor IL-10 can also serve as a potential diagnostic biomarker for MF-related anemia, possibly due to a compensatory response arising from reduced sensitivity of monocytes to IL-10.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.